Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 6Recruiting 3Terminated 2Active not recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Head & Neck 2Genitourinary 2Gastrointestinal 2Thoracic 1Other solid neoplasm 1NET 1Myeloid 1Lymphoid 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Head and Neck Neoplasms 276Squamous Cell Carcinoma of Head and Neck 242Carcinoma, Non-Small-Cell Lung 86Melanoma 68Neoplasms 61Colorectal Neoplasms 52Neoplasm Metastasis 48Carcinoma, Squamous Cell 48Thyroid Neoplasms 47Breast Neoplasms 41Carcinoma, Renal Cell 36Lung Neoplasms 34Ovarian Neoplasms 33Oropharyngeal Neoplasms 30Stomach Neoplasms 29Mouth Neoplasms 29Nasopharyngeal Carcinoma 28Triple Negative Breast Neoplasms 27Uterine Cervical Neoplasms 25Sarcoma 25Laryngeal Neoplasms 24Pancreatic Neoplasms 23Esophageal Neoplasms 23Salivary Gland Neoplasms 21Urinary Bladder Neoplasms 20Recurrence 19Small Cell Lung Carcinoma 18Nasopharyngeal Neoplasms 18Carcinoma, Transitional Cell 17Prostatic Neoplasms 16

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Etoposide 1Disulfides 1Cyclophosphamide 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Endocrine Gland Neoplasms × Head & Neck × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT03420963 2026-03-20

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Terminated
12 enrolled
DermatologicGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Bone Neoplasms, Endocrine Gland Neoplasms, Melanoma, Mouth Neoplasms, Pharyngeal Neoplasms, Sarcoma, Skin Neoplasms, Thyroid Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡